Panacea Biotec Overview
- Year Founded
-
1984
- Status
-
Public
- Employees
-
2,360
- Stock Symbol
-
531349
- Investments
-
1
- Share Price
-
$3.60
- (As of Friday Closing)
Panacea Biotec General Information
Description
Panacea Biotec Ltd research-based biotechnology company engaged in the business of research, development, manufacture, and marketing of vaccines in India and international markets. Through its subsidiary company, the company is engaged in the business of research, development, manufacture and marketing of branded pharmaceutical formulations and nutritional products in India and international markets. The company's reportable segments are: a. Vaccines, b. Pharmaceutical formulations & Nutrition. It generates maximum revenue from the Vaccines segment. The company has a business presence in India and Outside India, with the maximum revenue derived from the overseas market.
Contact Information
Website
www.panaceabiotec.comCorporate Office
- B-1 Extension G-3
- Mohan Co-operative Industrial Estate, Mathura Road
- New Delhi, Delhi 110044
- India
Corporate Office
- B-1 Extension G-3
- Mohan Co-operative Industrial Estate, Mathura Road
- New Delhi, Delhi 110044
- India
Panacea Biotec Stock Performance
As of 20-Nov-2026, Panacea Biotec’s stock price is $3.60. Its current market cap is $220M with 61.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.60 | $3.78 | $3.09 - $6.77 | $220M | 61.1M | 5K | -$0.01 |
Panacea Biotec Financials Summary
As of 30-Jun-2026, Panacea Biotec has a trailing 12-month revenue of $74.2M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2026 31-Mar-2026 | FY 2025 31-Mar-2025 | FY 2024 31-Mar-2024 |
|---|---|---|---|---|
| EV | 354,534 | 179,795 | 293,383 | 69,104 |
| Revenue | 74,229 | 69,029 | 58,256 | 66,669 |
| EBITDA | 3,154 | 3,049 | 2,611 | 3,921 |
| Net Income | (786) | (609) | (990) | (142) |
| Total Assets | 133,772 | 150,778 | 148,791 | |
| Total Debt | 0 | 1,590 | 1,754 | 1,799 |
Panacea Biotec Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Panacea Biotec Comparisons
Industry
Financing
Details
Panacea Biotec Competitors (37)
One of Panacea Biotec’s 37 competitors is Biocon, a Formerly PE-Backed company based in Bengaluru, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Biocon | Formerly PE-Backed | Bengaluru, India | ||||
| Glenmark Pharmaceuticals | Corporation | Mumbai, India | ||||
| Zydus Lifesciences | Corporation | Ahmedabad, India | ||||
| Sun Pharmaceutical Industries | Corporation | Mumbai, India | ||||
| Alkem Laboratories | Formerly PE-Backed | Mumbai, India |
Panacea Biotec Patents
Panacea Biotec Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4812183-A1 | Immunogenic composition of haemophilus influenzae conjugated to protein d | Pending | 21-Nov-2023 | ||
| WO-2025109417-A1 | Immunogenic composition of haemophilus influenzae conjugated to protein d | Inactive | 21-Nov-2023 | ||
| EP-3355916-A1 | Stable live attenuated recombinant dengue vaccine | Pending | 30-Sep-2015 | ||
| EP-3355916-A4 | Stable live attenuated recombinant dengue vaccine | Pending | 30-Sep-2015 | ||
| US-11123420-B2 | Stable live attenuated recombinant dengue vaccine | Active | 30-Sep-2015 | A61K39/12 |
Panacea Biotec Signals
Panacea Biotec Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Panacea Biotec Investments (1)
Panacea Biotec’s most recent deal was a Later Stage VC with Cambridge Biostability for . The deal was made on 06-Dec-2006.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cambridge Biostability | 06-Dec-2006 | Later Stage VC | Biotechnology |
Panacea Biotec ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Panacea Biotec Exits (1)
Panacea Biotec’s most recent exit was on 06-Dec-2006 from Cambridge Biostability. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Cambridge Biostability | 06-Dec-2006 | Completed |
|
Panacea Biotec FAQs
-
When was Panacea Biotec founded?
Panacea Biotec was founded in 1984.
-
Where is Panacea Biotec headquartered?
Panacea Biotec is headquartered in New Delhi, India.
-
What is the size of Panacea Biotec?
Panacea Biotec has 2,360 total employees.
-
What industry is Panacea Biotec in?
Panacea Biotec’s primary industry is Pharmaceuticals.
-
Is Panacea Biotec a private or public company?
Panacea Biotec is a Public company.
-
What is Panacea Biotec’s stock symbol?
The ticker symbol for Panacea Biotec is 531349.
-
What is the current stock price of Panacea Biotec?
As of 20-Nov-2026 the stock price of Panacea Biotec is $3.60.
-
What is the current market cap of Panacea Biotec?
The current market capitalization of Panacea Biotec is $220M.
-
What is Panacea Biotec’s current revenue?
The trailing twelve month revenue for Panacea Biotec is $74.2M.
-
Who are Panacea Biotec’s competitors?
Biocon, Glenmark Pharmaceuticals, Zydus Lifesciences, Sun Pharmaceutical Industries, and Alkem Laboratories are some of the 37 competitors of Panacea Biotec.
-
What is Panacea Biotec’s annual earnings per share (EPS)?
Panacea Biotec’s EPS for 12 months was -$0.01.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process